Health Canada's delays are delaying Canadians to lower-cost medicines—and costing them millions of dollars in the process. In fact, some generic submissions have faced delays of more than two years, keeping affordable options out of reach for far too long. As CGPA President Jim

The International Generic and Biosimilar Medicines Association (IGBA), which represents global manufacturers of generic and biosimilar medicines, announced today that CGPA and Biosimilars Canada President Jim Keon has assumed the role of IGBA Chair for 2026. In this third stint

Increasing use of generic medicine by a single percentage point would go a long way to making Canada's healthcare system more responsive and sustainable. How long? If the public sector increased its use of generic medicines by just 1%, it would save $514 million per year. If

Four members of the CGPA and Biosimilars Canada – Guillaume Lefèvre, Ken Gagnon, Christine Renaud, and Christian Kindundu – led a dynamic and diverse panel in a TED Talk-inspired format during the 19th edition of the Québec City Healthcare Industry Forum, held at the Québec City

https://t.co/NkhYRWE3eU

A small change in Alberta could have a big impact. If the province increased its use of generic medicines by just 1%, Albertans could save $122.6 million every year on prescription drugs. The private sector alone would save $68.8 million, while the public sector would save

Congratulations to CGPA member company, Marcan Pharmaceuticals Earlier this week, members of the CGPA leadership team, including President Jim Keon, Vice President of Federal and International Affairs Jody Cox, and Kristin Willemsen, Vice President of Scientific and Regulatory

The federal budget tabled on November 4 includes important measures to support domestic life sciences and manufacturing investments. Budget 2025 did not provide the resources Health Canada urgently needs to address its growing backlog of generic and biosimilar drug submissions.

The CGPA and its member companies would like to thank The Hon. @VictorFedeli Ontario’s Minister of Economic Development, Job Creation and Trade, along with The Hon. @ninatangri , and MPPs John Jordan, Frances Gélinas, and Lee Fairclough for meeting with us at Queen’s Park

Time for Action: Investing in Health Canada to Accelerate Access to Affordable Medications, Jim Keon writes https://t.co/1kTODH8eNh @CdnGenerics

In a new op-ed for National Newswatch, Jim Keon, the president of CGPA and its Biosimilars Canada division, calls on the federal government to invest in Health Canada's drug review capacity to accelerate access to cost-saving generics and biosimilars. As Jim’s piece notes, right

In British Columbia, a small shift could mean big savings. If BC increased its use of generic medicines by just 1%, the province could save more than $112 million per year on prescription drugs. Yes, you read that right: more than $100 million in savings with just a 1% increase

The CGPA welcomes the decision by Quebec’s Ministry of Health and Social Services to increase the number of formulary updates to the lists of medications from 9 to 12 per year starting in 2026. This decision reflects Minister Christian Dubé’s clear commitment to accelerating

Every small shift toward generic medicine adds up—and in Quebec's case, it adds up to a lot. Did you know that Quebec could save more than a quarter billion dollars by increasing its use of generic medicines by just 1%? It's true. A 1% increase in generics would save Quebec's

If Canada's most populous province increased its use of generic pharmaceuticals by just 1%, the province could reduce their spending by almost half a billion dollars. Yes, half a billion. That’s such a large number that it's almost hard to believe, but it's true. If Ontario's

When you pick up a generic prescription, you’re getting the exact same active ingredient, in the same amount, working the same way in your body as the brand-name drug. The only real difference? The price. The brand-name version of prescription medicines can cost up to 10 times

Did you know that more than three-quarters of the medicines Canadians rely on every day are generic? More than 77% of prescriptions filled in Canada are generics, because they deliver the same quality, safety, and effectiveness as brand-name drugs at just a fraction of the cost

The most boring conversation ever? Maybe not!!! Check out the second TV spot from our first-ever TV ad campaign. In this episode, "Generic" and "Brand Name" continue their argument about whether generic prescription medicines are as effective as their brand name counterparts.

Improving the efficiency of Health Canada’s drug review process is a shared priority for federal Health Minister Marjorie Michel, the CGPA and its @CDNBiosimilars division. We look forward to working with Health Canada to cut red tape and speed up generic and biosimilar drug